Choi, Yewon published the artcileSafety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects, Related Products of oxazolidine, the publication is Journal of Antimicrobial Chemotherapy (2018), 73(1), 183-190, database is CAplus and MEDLINE.
Background: LCB01-0371 is a new oxazolidinone antibiotic, which targets most Gram-pos. organisms. High rates of adverse reactions including myelosuppression have been reported for existing oxazolidinones, limiting their long-term use. Objectives: The safety, tolerability and pharmacokinetics (PK) of 21 day multiple oral administrations of LCB01-0371 in healthy male subjects (clinicaltrials.gov: NCT02540460) were investigated. Methods: In this randomized, double-blind, placebo-controlled study, subjects received 800mg of LCB01-0371 once or twice daily or 1200mg of LCB01-0371 twice-daily for 21 days in a fasting state. Safety and tolerability profiles including laboratory tests were evaluated during the study and on a post-study visit and the results were analyzed using repeated-measures anal. of variance (RM-ANOVA). Serial blood samples for PK anal. were collected up to 12 h after dosing on day 21. Results: A total of 40 subjects were enrolled and 34 subjects completed the study. Two subjects dropped out according to stopping rules. In the 1200mg twice-daily dose group, the absolute value of red blood cell count, haematocrit and Hb decreased by 500×106/L (6.5%), 4.5% (6.8%) and 1.6 g/dL (6.9%), resp., after 21 day administrations of LCB01-0371. However, mean relative changes from baseline of all haematol. values were not significantly different among doses, including placebo (all, P<0.05). PK profiles of LCB01-0371 in the dose range of 800mg once daily to 1200mg twice daily were consistent with previous studies. Conclusions: LCB01-0371 is well tolerated in healthy male subjects with comparable haematol. profiles to placebo, after multiple doses of up to 1200mg twice daily for 21 days.
Journal of Antimicrobial Chemotherapy published new progress about 1219707-39-7. 1219707-39-7 belongs to oxazolidine, auxiliary class Other Aliphatic Heterocyclic,Oxazolidine,Chiral,Fluoride,Benzene,Amide,Alcohol,Anti-infection, name is (R)-3-(3-Fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one, and the molecular formula is C14H17FN4O3, Related Products of oxazolidine.
Referemce:
https://en.wikipedia.org/wiki/Oxazolidine,
Oxazolidine | C3H7NO – PubChem